Selecta Biosciences, Inc.
SELB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $21 |
| % Growth | 51.7% | -72.9% | -94.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $3 |
| Gross Profit | $0 | $0 | $0 | $19 |
| % Margin | 0% | 0% | 0% | 88.2% |
| R&D Expenses | $14 | $15 | $15 | $4 |
| G&A Expenses | $8 | $7 | $8 | $12 |
| SG&A Expenses | $8 | $7 | $8 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $22 | $23 | $16 |
| Operating Income | $0 | -$22 | $0 | $50 |
| % Margin | 0% | -7,319.1% | 0% | 236.5% |
| Other Income/Exp. Net | $0 | $38 | $0 | -$85 |
| Pre-Tax Income | -$36 | $16 | -$18 | -$35 |
| Tax Expense | $0 | $0 | $0 | -$5 |
| Net Income | -$36 | $16 | -$18 | -$31 |
| % Margin | -7,942.9% | 5,330.9% | -1,610% | -147.7% |
| EPS | -1.38 | 0.51 | -0.11 | -0.2 |
| % Growth | -370.6% | 563.6% | 45% | – |
| EPS Diluted | -1.38 | 0.5 | -0.11 | -0.2 |
| Weighted Avg Shares Out | 26 | 26 | 155 | 155 |
| Weighted Avg Shares Out Dil | 26 | 26 | 155 | 155 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $6 |
| Interest Expense | $0 | $0 | $0 | -$3 |
| Depreciation & Amortization | $1 | $0 | $0 | -$1 |
| EBITDA | -$35 | -$22 | $0 | -$40 |
| % Margin | -7,808.8% | -7,319.1% | 0% | -189.5% |